Hearing on HIV medicine patent appeal

• Lenacapavir, administered twice-yearly, has shown superior efficacy in HIV prevention trials.
• Sankalp, a civil society organization, opposes the patent applications, arguing the drug is a known compound and should not be considered an invention under India’s Patent Act.
• Granting these patents could restrict access to affordable generic versions of Lenacapavir, crucial for global HIV care.